Literature DB >> 374017

Endotracheally administered antibiotics for gram-negative bronchopneumonia.

J Klastersky, F Carpentier-Meunier, L Kahan-Coppens, J P Thys.   

Abstract

Sisomicin or a placebo was administered endotracheally to two groups of 18 and 20 unconscious patients, respectively, who had tracheostomies or endotracheal tubes in place and developed a severe gram-negative broncho-pneumonia. In addition, the patients received systemically a combination of sisomicin and carbenicillin. A favorable clinical response was obtained in 14 (77 percent) of the 18 patients who were treated with sisomicin and in nine (45 percent) of the 20 patients who received the placebo (P less than 0.05). Endotracheal therapy with sisomicin was well tolerated and resulted in high levels of sisomicin and in elevated bactericidal activity within the bronchial secretions. Endotracheally administered amino-glycosides might be an important adjunct to systemically administered antibiotics in the management of severe gram-negative bronchopneumonia.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 374017     DOI: 10.1378/chest.75.5.586

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  14 in total

Review 1.  Aerosolised antibacterials for the prevention and treatment of hospital-acquired pneumonia.

Authors:  G Christopher Wood; Joseph M Swanson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

2.  Liquid dose pulmonary instillation of gentamicin PulmoSpheres formulations: tissue distribution and pharmacokinetics in rabbits.

Authors:  D J Smith; L M Gambone; T Tarara; D R Meays; L A Dellamary; C M Woods; J Weers
Journal:  Pharm Res       Date:  2001-11       Impact factor: 4.200

Review 3.  Drug treatment of pneumonia in the hospital. What are the choices?

Authors:  M Aoun; J Klastersky
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

Review 4.  Nosocomial pneumonia in patients in intensive care units.

Authors:  S D Podnos; G B Toews; A K Pierce
Journal:  West J Med       Date:  1985-11

5.  Systemic absorption of endotracheally administered aminoglycosides in seriously ill patients with pneumonia.

Authors:  S S Crosby; W A Edwards; C Brennan; E P Dellinger; L A Bauer
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

6.  Bronchial secretion levels of amikacin.

Authors:  W L Dull; M R Alexander; J E Kasik
Journal:  Antimicrob Agents Chemother       Date:  1979-12       Impact factor: 5.191

7.  Moxalactam therapy of serious infections.

Authors:  P Van der Auwera; N Clumeck; Y Van Laethem; R Vanhoof; J P Butzler
Journal:  Infection       Date:  1983 Jul-Aug       Impact factor: 3.553

8.  Amikacin levels in bronchial secretions of 10 pneumonia patients with respiratory support treated once daily versus twice daily.

Authors:  C Santré; H Georges; J M Jacquier; O Leroy; C Beuscart; D Buguin; G Beaucaire
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

9.  Penetration of enoxacin into bronchial secretions.

Authors:  I W Fong; A Vandenbroucke; M Simbul
Journal:  Antimicrob Agents Chemother       Date:  1987-05       Impact factor: 5.191

Review 10.  Inhaled therapeutics for prevention and treatment of pneumonia.

Authors:  Amar Safdar; Samuel A Shelburne; Scott E Evans; Burton F Dickey
Journal:  Expert Opin Drug Saf       Date:  2009-07       Impact factor: 4.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.